Ischaemic conditioning to improve patient and organ outcomes after kidney transplantation Authors: Robert Stabler, Helen McKenna, Madelaine Gimzewska, Dan Harvey, Muhammad A Khurram, Kieran Mccafferty, Kristin Veighey, Jeremy Fabes, supported by the Cochrane Kidney and Transplant Review Group Published: 2026 ABSTRACT ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:To evaluate the benefits and harms of ischaemic conditioning on patient and organ outcomes in kidney transplantation. Background Description of the condition Kidney transplantation is the best treatment for kidney failure that requires dialysis, improving outcomes and quality of life (QoL) and saving the NHS around £25,000/year per person [1, 2]. However, organ shortages have left over 9,700 people waiting over three years on dialysis with falling QoL and 5% to 10% annual mortality [3]. Meanwhile, organ demand continues to grow, and transplant failure causes 600 transplant recipients to return to the waiting list annually [2]. Transplant failure is multi‐factorial, resulting in progressive decline in function. The better the initial post‐transplant kidney (graft) function, measured by the estimated glomerular filtration rate (eGFR), the longer a graft lasts and the recipient remains off dialysis and the transplant waiting list [4]. Initial graft function is dependent on the severity of ischaemia‐reperfusion injury (IRI) during transplantation, where the organ blood supply is interrupted on retrieval (ischaemic injury) and restored in the recipient (reperfusion injury). IRI comprises multiple parallel and interacting pathways that lead to further tissue damage following an ischaemic insult. These include a local and systemic inflammatory response with immune cell activation, mitochondrial dysfunction, the production of reactive oxygen species leading to cellular damage, increased cellular permeability, and disruption of the vascular endothelium [5]. IRI mediates poor outcomes such as delayed graft function (DGF), acute and chronic rejection, transplant failure, recipient morbidity and death [6]. Maximising the function of a transplanted kidney is of utmost importance: lower kidney function following transplantation predicts graft failure, necessitating a return to dialysis or further transplantation surgery, and death. These outcomes lead to significant patient morbidity, deterioration in QoL, as well as substantial healthcare costs. Description of the intervention and how it might work Ischaemic conditioning comprises brief and repetitive cycles of sub‐noxious ischaemia and reperfusion of the limbs or internal organs to induce local organ and systemic protection against subsequent IRI [7]. Conditioning treatments may be applied to the organ donor, the recipient, or both, before, during or after transplant surgery and may be non‐invasive (i.e. blood pressure cuff) or invasive (i.e. arterial clamping) [8]. Treatments may be applied directly, modifying the blood supply to the organ to be donated, or indirectly, causing ischaemia of a limb or other structure, thereby inducing systemic effects. Indirect ischaemic conditioning, also known as remote ischaemic conditioning, is a specific form of conditioning in which treatment of one limb or organ can confer protection to a distant target organ, thought to be mediated through neuronal and humoral signals. Ischaemic conditioning works through multiple parallel pathways that are still being elucidated [8]. A key mechanism involves inhibition of mitochondrial permeability transition pore (mPTP) opening through the PI3‐K/AKT/PKB pathway, which is necessary for cell death following ischaemic injury. Ischaemic conditioning also upregulates the expression of protective proteins such as iNOS (inducible nitric oxide synthase), COX‐2 (cyclooxygenase‐2), and anti‐apoptotic proteins via NF‐kB and other transcription factors. Other potential protective mechanisms include the induction of heat shock proteins, which help stabilise cellular proteins during stress, and the activation of the autophagy pathway, which removes damaged cellular components. Why it is important to do this review Ischaemic conditioning presents an opportunity to reduce IRI and thereby improve post‐transplant organ function (eGFR), extend transplant lifespan, keep people free of dialysis for longer, reduce organ demand, yield health and QoL benefits and reduce costs. Transplant organ longevity and its associated patient and population benefits are top 10 priorities as defined by clinicians and public expert participants as part of the James Lind Priority Setting Partnership for Kidney Transplant, and well‐represented in the current recommended outcome sets for kidney transplantation [9, 10]. While clinical trials of ischaemic conditioning in kidney transplantation have suggested improvements in death, graft loss and DGF, none have sufficient independent power to result in a change to clinical practice. The topic has been previously meta‐analysed, but with methodological concerns, and potential errors in data extraction and analysis that have limited the conclusions which can be drawn [11, 12, 13]. These analyses did not include data on long‐term outcomes, despite these being the main patient‐centred outcomes and published data being available in the largest trials. This has led to a lack of clarity around conditioning in kidney transplantation, leading to a failure of translation to clinical practice. Accurate analysis of long‐term outcomes is necessary to provide a transparent synthesis of the data and guide future research and clinical management. Objectives To evaluate the benefits and harms of ischaemic conditioning on patient and organ outcomes in kidney transplantation. Methods We will follow the Methodological Expectations for Cochrane Intervention Reviews (MECIR) when conducting the review [14], and PRISMA 2020 for the reporting [15]. Criteria for considering studies for this review Types of studies We will consider randomised controlled trials (RCTs) that evaluate a form of ischaemic conditioning in either the organ donor, recipient or both, in live‐ or deceased‐donor kidney transplantation. Studies may be available in full‐text or abstract form, or unpublished, with no restrictions on language or publication year. Open‐label trials will be eligible. We will include trials with and without prospective registration; where lacking, this will be highlighted and included in risk of bias considerations, especially for final reports published after 2010. We will not include quasi‐RCTs (assignment to an intervention using methods that are not formally random) due to the potential for confounding. Types of participants We will include studies of adults and children undergoing live‐ or deceased‐donor kidney transplantation. There will be no age, sex, or comorbidity limitations. Participants undergoing multi‐organ transplantation or re‐transplantation will be included. When a trial includes a mixed population, we will only use the data for our population of interest. If these data are not available, either in the report or through contacting the corresponding author, we will include the study only if at least 80% of the sample size is from our population of interest. Types of interventions The interventions of interest in this review are different ways of applying ischaemic conditioning. Ischaemic conditioning may be performed on the kidney donor, the recipient or both.The delivery of the ischaemic conditioning stimulus may be non‐invasive (e.g. blood pressure cuff) or invasive (e.g. vascular clamping by a surgeon).Ischaemic conditioning may be direct (applied to the kidney itself) or indirect (applied to the participant’s limb).Ischaemic conditioning may be applied at any reasonable time point perioperatively.Pre‐conditioning: prior to organ retrieval surgery (donor), transplant surgery (recipient) or both.Per‐conditioning: during organ ischaemia but prior to reperfusion in the recipient.Post‐conditioning: at the onset, or following, organ reperfusion in the recipient. Ischaemic conditioning may be performed on the kidney donor, the recipient or both. Ischaemic conditioning may be performed on the kidney donor, the recipient or both. The delivery of the ischaemic conditioning stimulus may be non‐invasive (e.g. blood pressure cuff) or invasive (e.g. vascular clamping by a surgeon). The delivery of the ischaemic conditioning stimulus may be non‐invasive (e.g. blood pressure cuff) or invasive (e.g. vascular clamping by a surgeon). Ischaemic conditioning may be direct (applied to the kidney itself) or indirect (applied to the participant’s limb). Ischaemic conditioning may be direct (applied to the kidney itself) or indirect (applied to the participant’s limb). Ischaemic conditioning may be applied at any reasonable time point perioperatively.Pre‐conditioning: prior to organ retrieval surgery (donor), transplant surgery (recipient) or both.Per‐conditioning: during organ ischaemia but prior to reperfusion in the recipient.Post‐conditioning: at the onset, or following, organ reperfusion in the recipient. Ischaemic conditioning may be applied at any reasonable time point perioperatively. Pre‐conditioning: prior to organ retrieval surgery (donor), transplant surgery (recipient) or both. Pre‐conditioning: prior to organ retrieval surgery (donor), transplant surgery (recipient) or both. Per‐conditioning: during organ ischaemia but prior to reperfusion in the recipient. Per‐conditioning: during organ ischaemia but prior to reperfusion in the recipient. Post‐conditioning: at the onset, or following, organ reperfusion in the recipient. Post‐conditioning: at the onset, or following, organ reperfusion in the recipient. Any duration, frequency and number of conditioning treatments may be applied at any pressure using any technique anticipated to induce distal ischaemia. We will base comparisons on the interventions grouped as follows. Any form of ischaemic conditioning;AND subgroup analyses based on the type of ischaemic conditioning performedAND sub‐group analyses based on whether the donor, the recipient or both participants undergo ischaemic conditioning.Placebo, sham conditioning or another form of ischaemic conditioning. Any form of ischaemic conditioning;AND subgroup analyses based on the type of ischaemic conditioning performedAND sub‐group analyses based on whether the donor, the recipient or both participants undergo ischaemic conditioning. Any form of ischaemic conditioning; AND subgroup analyses based on the type of ischaemic conditioning performed AND subgroup analyses based on the type of ischaemic conditioning performed AND sub‐group analyses based on whether the donor, the recipient or both participants undergo ischaemic conditioning. AND sub‐group analyses based on whether the donor, the recipient or both participants undergo ischaemic conditioning. Placebo, sham conditioning or another form of ischaemic conditioning. Placebo, sham conditioning or another form of ischaemic conditioning. Where a sham intervention is provided, this may be the application of a cuff or similar device, which is then not inflated, or a low‐pressure sham intervention may be delivered, typically below diastolic blood pressure, such that no ischaemic stimulus would be expected to ensue. Where studies include an active comparator, this may be the same conditioning modality but using an alternative site of application, duration of intervention, applied pressure, number of cycles or another reasonable difference. Studies comparing alternative forms of conditioning (e.g. invasive and non‐invasive or direct and indirect) will be accepted, as well as those comparing different intervention timings (i.e. pre‐ versus post‐conditioning). Outcome measures The outcomes selected include the relevant Standardised Outcomes in Nephrology (SONG) core outcome sets for transplantation (SONG‐Tx) as specified by the SONG initiative [9]. Cardiovascular disease, infection and cancer are predominantly due to chronic immunosuppression as well as pre‐transplant disease and are not expected to be affected by the use of ischaemic conditioning, hence are not included as outcomes in this review. Typical time points in kidney transplant studies are at 3, 6, 12, 36, and 60 months post‐transplant. If study time points align poorly, we will group outcomes into three time periods. Early: zero to three months post‐transplant.Intermediate: three to 12 months post‐transplant.Late: 12 to 60 months post‐transplant. Early: zero to three months post‐transplant. Early: zero to three months post‐transplant. Intermediate: three to 12 months post‐transplant. Intermediate: three to 12 months post‐transplant. Late: 12 to 60 months post‐transplant. Late: 12 to 60 months post‐transplant. If outcome groups are used, when an outcome is reported more than once within a time period, we will use data from the latest time point within that period or the time point that correlates best with other studies within that period. Critical outcomes The SONG‐Tx outcome set identified critical outcomes as being the most important to public experts and clinicians [9]. eGFR (mL/min/1.73 m2, per the MDRD or CKD‐EPI equation), where possible adjusted for death or graft lossa (at given time point).Participant survival post‐transplant (days) or death (any cause) (at given time point).Graft survival post‐transplant (days) or graft loss (at given time point) in a live participant (as defined by reporting studies).Transplant survival: earliest of participant death or graft loss (days, or at a given time point, as defined by reporting studies).DGF (days; defined as the need for dialysis in the first post‐operative week and/or as per study criteria).Serious adverse eventsb attributed to conditioning intervention (at given time point).Participant‐reported outcome measures post‐operatively (typically EQ‐5D‐5L [16], KDQoL [17] or SF‐36 [18]), at a given time point. eGFR (mL/min/1.73 m2, per the MDRD or CKD‐EPI equation), where possible adjusted for death or graft lossa (at given time point). eGFR (mL/min/1.73 m2, per the MDRD or CKD‐EPI equation), where possible adjusted for death or graft lossa (at given time point). Participant survival post‐transplant (days) or death (any cause) (at given time point). Participant survival post‐transplant (days) or death (any cause) (at given time point). Graft survival post‐transplant (days) or graft loss (at given time point) in a live participant (as defined by reporting studies). Graft survival post‐transplant (days) or graft loss (at given time point) in a live participant (as defined by reporting studies). Transplant survival: earliest of participant death or graft loss (days, or at a given time point, as defined by reporting studies). Transplant survival: earliest of participant death or graft loss (days, or at a given time point, as defined by reporting studies). DGF (days; defined as the need for dialysis in the first post‐operative week and/or as per study criteria). DGF (days; defined as the need for dialysis in the first post‐operative week and/or as per study criteria). Serious adverse eventsb attributed to conditioning intervention (at given time point). Serious adverse eventsb attributed to conditioning intervention (at given time point). Participant‐reported outcome measures post‐operatively (typically EQ‐5D‐5L [16], KDQoL [17] or SF‐36 [18]), at a given time point. Participant‐reported outcome measures post‐operatively (typically EQ‐5D‐5L [16], KDQoL [17] or SF‐36 [18]), at a given time point. a eGFR adjustment for death or graft loss by defining patients who have died or suffered graft loss as having an eGFR of 0 mL/min/1.73 m2 or another appropriate value. b Serious adverse events are any undesirable event attributed to the intervention that threatens life, requires hospitalisation or results in persistent or significant disability. Important outcomes Acute rejection (cellular, humoral, vascular involvement; as defined by reporting studies).Chronic rejection (cellular, humoral, vascular involvement; as defined by reporting studies).Length of hospital stay (days).Proteinuria or albuminuria (as defined by reporting studies).Cardiovascular complication (as defined by reporting studies).IRI (biochemical or other criteria, as defined by reporting studies).Non‐serious adverse events attributed to conditioning intervention (at a given time point). Non‐serious adverse events: any undesirable event attributed to the intervention that does not threaten life, require hospitalisation, or result in persistent or significant disability. Acute rejection (cellular, humoral, vascular involvement; as defined by reporting studies). Acute rejection (cellular, humoral, vascular involvement; as defined by reporting studies). Chronic rejection (cellular, humoral, vascular involvement; as defined by reporting studies). Chronic rejection (cellular, humoral, vascular involvement; as defined by reporting studies). Length of hospital stay (days). Length of hospital stay (days). Proteinuria or albuminuria (as defined by reporting studies). Proteinuria or albuminuria (as defined by reporting studies). Cardiovascular complication (as defined by reporting studies). Cardiovascular complication (as defined by reporting studies). IRI (biochemical or other criteria, as defined by reporting studies). IRI (biochemical or other criteria, as defined by reporting studies). Non‐serious adverse events attributed to conditioning intervention (at a given time point). Non‐serious adverse events: any undesirable event attributed to the intervention that does not threaten life, require hospitalisation, or result in persistent or significant disability. Non‐serious adverse events attributed to conditioning intervention (at a given time point). Non‐serious adverse events: any undesirable event attributed to the intervention that does not threaten life, require hospitalisation, or result in persistent or significant disability. Search methods for identification of studies Electronic searches We will search the following databases for RCTs using the RCT filter suggested in Technical Supplement to Chapter 4 of the Cochrane Handbook for Systematic Reviews of Interventions [19, 20]. We will not apply language, publication year or publication status restrictions. Cochrane Central Register of Controlled Trials (CENTRAL; latest issue) via the Cochrane LibraryOvid Medline® ALL (1946 to present)Embase Classic and Ovid Embase (1947 to present)Web of Science Conference Proceedings Citation IndexCochrane Kidney and Transplant Specialised Register via MeerKatPubMed (in‐process and e‐publications ahead of print only)US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (https://www.clinicaltrials.gov)World Health Organization International Clinical Trials Registry Platform (https://trialsearch.who.int)The ISRCTN registry (https://www.isrctn.com/) Cochrane Central Register of Controlled Trials (CENTRAL; latest issue) via the Cochrane Library Cochrane Central Register of Controlled Trials (CENTRAL; latest issue) via the Cochrane Library Ovid Medline® ALL (1946 to present) Ovid Medline® ALL (1946 to present) Embase Classic and Ovid Embase (1947 to present) Embase Classic and Ovid Embase (1947 to present) Web of Science Conference Proceedings Citation Index Web of Science Conference Proceedings Citation Index Cochrane Kidney and Transplant Specialised Register via MeerKat Cochrane Kidney and Transplant Specialised Register via MeerKat PubMed (in‐process and e‐publications ahead of print only) PubMed (in‐process and e‐publications ahead of print only) US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (https://www.clinicaltrials.gov) US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (https://www.clinicaltrials.gov) World Health Organization International Clinical Trials Registry Platform (https://trialsearch.who.int) World Health Organization International Clinical Trials Registry Platform (https://trialsearch.who.int) The ISRCTN registry (https://www.isrctn.com/) The ISRCTN registry (https://www.isrctn.com/) We present the Medline subject search strategy in Supplementary material 1. This will be peer reviewed by an experienced information specialist using the PRESS checklist [21]. The Medline search strategy will be adapted as necessary for other databases. We will report the number of papers retrieved, assessed, included, and excluded in the review. We will report papers that require translation, either to assess eligibility or as part of data extraction. Searching other resources We will handsearch the reference lists of included studies and any relevant systematic reviews identified for further references to relevant studies. We will check the included studies for retractions and errata via the Retraction Watch Database and report the search dates in the review (https://retractiondatabase.org). We will search Epistemonikos (https://www.epistemonikos.org) and PROSPERO (https://www.crd.york.ac.uk/prospero/) for related systematic reviews. We may contact the original authors or funders of included studies for clarification and further data if the study reports are unclear. Data collection and analysis Review authors who were directly involved in a study included in the searches or review will not make study eligibility decisions about, extract data from, carry out the risk of bias assessment for, or perform GRADE assessments of that study. Selection of studies Two review authors (HM, MG) will independently screen each title and abstract identified in the searches against the review inclusion criteria. Any disagreements will be referred to a third review author (JF or KV) as required. This review will follow the PRISMA reporting guidelines [15] and include a PRISMA‐compliant flow diagram outlining the search and study selection process. Search results will be combined in Covidence [22], duplicates excluded, and screened at the title and abstract levels, and then at the full‐text level prior to a final inclusion decision. Where material of interest identified in the searches is only available in a non‐English format, we will use DeepL [www.deepl.com/en/translator] or Google Translate [translate.google.co.uk/] during screening and data extraction. If the output does not permit a screening decision or there are uncertainties relating to study data extraction, we will seek support from a native speaker of the document language. Data extraction and management Data extraction will be performed using a digital form developed by three review authors (HM, MG, JF). We will pilot the form on three studies to ensure all relevant review data is captured. Two review authors (HM, MG) will independently perform data extraction, with post‐collection comparison to identify discrepancies, and a third review author (JF or KV) will review where necessary. Data will be extracted to describe study publication year and authorship, study design, the trial population (sample size, number in each trial arm, proportions of live‐ and deceased donor transplants), intervention (type and timing of ischaemic conditioning, details of application and dose), control or comparators and outcomes. Data required to complete a risk of bias assessment will also be extracted, including randomisation methods, allocation concealment, blinding, frequency and handling of missing data, protocol deviations, adherence to intention‐to‐treat (ITT), and selective reporting of outcomes [23]. The presence of a pre‐trial registration will also be recorded. Where a review outcome of interest has not been reported by an included trial, we will attempt to contact the corresponding author (and others, where necessary) to obtain specific additional trial information. Where we identify abstracts, pre‐publication material, and other information that present data relevant to the review, we will endeavour to contact the authors for additional data. Data on covariates of interest that might influence the size of an intervention effect will be collected to enable subgroup and/or sensitivity analyses. These include participant age, the presence of general anaesthesia or sedation at the time of ischaemic conditioning, donor or recipient diabetes mellitus, the method of ischaemic conditioning (direct or indirect application), the use of ex vivo machine perfusion of the kidney before implantation (normothermic or hypothermic), the use of normothermic regional perfusion during organ retrieval, the type of organ donation (live‐donor or after circulatory death or death by neurological criteria), and kidney‐only or multi‐organ transplantation. Risk of bias assessment in included studies Risk of bias in included studies will be independently assessed by two review authors (HM, MG) using the Cochrane Risk of Bias 2 (RoB 2) tool [23]. Results will be compared and any discrepancies resolved through discussion with a third review author (JF or KV). We do not anticipate cluster‐RCTs or cross‐over RCTs, but if these are included, we will use the dedicated RoB 2 tool version with appropriate adjustments to the risk of bias assessment [24]. The effect of interest will be assigned to the intervention at baseline, regardless of whether the intervention is received as intended (i.e. effect). The risk of bias for each outcome will be assessed within the timeframes described in Outcome measures (early: zero to three months post‐transplant; intermediate: three to 12 months post‐transplant; late: 12 to 60 months post‐transplant). GRADE assessments will be informed by the risk of bias for each outcome in each predefined time frame. We will assess the risk of bias for the critical outcomes of eGFR (intermediate and late timeframes), patient survival post‐transplant or death (intermediate and late timeframes), graft survival post‐transplant or graft loss (intermediate and late timeframes), transplant survival or participant death/graft loss (intermediate and late timeframes), DGF (early timeframe), serious adverse events (early timeframe) and participant‐reported outcome measures (early and intermediate timeframes), and the important outcomes of acute rejection and chronic rejection (intermediate and late timeframes). The risk of bias will be summarised across domains. Risk of bias due to the randomisation process.Risk of bias due to deviations from the intended interventions.Risk of bias due to missing outcome data.Risk of bias in the measurement of the outcome.Risk of bias in the selection of the reported result. Risk of bias due to the randomisation process. Risk of bias due to the randomisation process. Risk of bias due to deviations from the intended interventions. Risk of bias due to deviations from the intended interventions. Risk of bias due to missing outcome data. Risk of bias due to missing outcome data. Risk of bias in the measurement of the outcome. Risk of bias in the measurement of the outcome. Risk of bias in the selection of the reported result. Risk of bias in the selection of the reported result. Each source of bias will be classified as 'low risk', 'some concerns' or 'high risk'. Based on the risk of bias in each domain, an overall risk of bias will be determined for each outcome using the RoB 2 algorithm [23, 25]. Where data relevant to the risk of bias assessment have not been reported, we will attempt to contact the corresponding author (and others, where necessary) to obtain specific additional trial information. We will use the Cochrane Excel tool with RoB 2 assessments (https://www.riskofbias.info/welcome/rob-2-0-tool) to support consensus decision‐making for signalling questions and to record and manage RoB 2 assessments. The risk of bias judgments (with notes and details of decisions, where necessary) will be available as additional appendices. The risk of bias assessment will inform the GRADE assessment and summary of findings table. Measures of treatment effect We will present the risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes. Where the number of observed events is small (< 5% of the sample per group) and trials have balanced treatment groups, we will report the Peto odds ratio (OR) with 95% CI [[26]. We will express treatment effects for continuous data outcomes as mean differences (MD) with 95% CI; if the outcomes are measured using different scales or instruments, we will use standardised mean differences (SMD) with 95% CI. If study time points do not align, we will use data from the last time point within our specified outcome timeframes (early, intermediate, late) as specified in this protocol. If adjusted data (for participant death and graft loss) are available for eGFR, we will prioritise their use. For graft survival, participant survival and transplant survival comparisons using time‐to‐event data, we will perform generic inverse variance meta‐analysis using hazard ratios (HR) and standard errors (SE) (log scale). If we include cluster‐RCTs, we will use the generic inverse‐variance approach in Review Manager (RevMan) [27], using adjusted odds reported in the studies and calculating SE from the 95% CIs provided using the formula: SE = (upper limit – lower limit)/3.92. Where a cluster‐RCT could contribute data to a meta‐analysis, we will report data for all contributing trials using the inverse‐variance approach. Unit of analysis issues For parallel‐design RCTs with two arms, the study participants in each trial arm will be the unit of analysis. For dichotomous outcomes that may occur multiple times (i.e. acute rejection), participants, rather than events, will be the unit of analysis. However, if incidence at a trial arm level is the only data available (rather than at a participant level) then we will analyse data in this manner. Where multi‐arm trials that contain two comparisons of interest (i.e. one form of ischaemic conditioning versus another form of ischaemic conditioning versus placebo) are included in the same meta‐analysis, we will either halve the comparison group data to avoid duplication or combine data from both intervention arms. We do not anticipate any cross‐over or cluster‐RCTs, but if these are included, we will analyse the results according to Chapter 23 of the Cochrane Handbook for Systematic Reviews of Interventions [24]. Dealing with missing data We will contact study authors to request missing or additional data, where necessary. Where it is unclear from a study report how missing data was handled, we will contact the authors for clarification. Where we cannot obtain missing data, we will report this as missing. All author communications will be documented in an appendix. We will record the number of participants lost to follow‐up for each trial. Where possible, we will analyse data on an ITT basis, but if insufficient data are available, we will also present a per‐protocol analysis. We will handle missing data using the approach discussed in Chapter 10 of the Cochrane Handbook for Systematic Reviews Interventions [26]. Reporting bias assessment Literature searches will be comprehensive and, where we meta‐analyse 10 or more studies, we will construct funnel plots and perform and Egger's regression test to determine possible publication bias [28]. Selective outcome reporting will be identified through comparison of study protocol and study reports. Synthesis methods We will perform meta‐analyses when two or more trials are sufficiently homogenous in terms of population, interventions, comparisons and outcomes. We will assess for statistical heterogeneity using the I2 test, with an I2 > 75% supporting a decision not to pool data. Studies will also be assessed for types and sources of heterogeneity, either clinical or methodological, when deciding whether to pool data. Meta‐analyses will be performed according to the Cochrane Handbook for Systematic Reviews of Interventions [26] and all statistical analyses undertaken in RevMan [27]. We will include all eligible studies, regardless of their risk of bias. We will use a random‐effects model to pool the data, as it considers the variability within a study as well as among studies, and we expect that the treatment effect will vary between studies due to heterogeneity. The Restricted Maximum Likelihood (REML) estimator will be used to estimate between‐trial variance. The Hartung‐Knapp‐Sidik‐Jonkman method will be used to calculate a CI for the meta‐analysis effect estimate when there are at least three studies, and the estimate of heterogeneity is greater than zero. In other scenarios (i.e. in pooled analyses of two studies or when the estimate of heterogeneity is zero), we will use the Wald‐type method. Where possible, we will combine data at common time points reported across trials; if necessary, we will group time points into early, intermediate, and late time periods. If meta‐analysis of an outcome is not feasible due to a lack of data or clinical/methodological heterogeneity preventing data pooling, we will conduct a narrative synthesis following the Synthesis Without Meta‐Analysis (SWiM) guidance [29]. Investigation of heterogeneity and subgroup analysis Statistical heterogeneity will be assessed through visual inspection of forest plots and using the I² statistic. An I² statistic of 0% to 40% will be of low concern, 30% to 60% likely represents moderate heterogeneity, 50% to 75% represents probable substantial heterogeneity, and 75% to 100% represents considerable heterogeneity [30]. Possible reasons for heterogeneity will be explored through subgroup analysis, depending on the number of studies available for each analysis. If we cannot identify the cause of heterogeneity, we will downgrade the certainty of the evidence due to inconsistency during GRADE assessments [31]. We will perform subgroup analyses, if data permits, using the following subgroups. Age: adult versus childrenType of organ donation: live‐donor versus deceased donor kidney, and if appropriate:Donation after cardiac death versus donation after death by neurological criteria.Participant treated: kidney donor, recipient or both participantsMode of treatment delivery: non‐invasive versus invasiveDirectness of treatment: direct versus indirectTiming: pre‐conditioning, per‐conditioning or post‐conditioning. Age: adult versus children Age: adult versus children Type of organ donation: live‐donor versus deceased donor kidney, and if appropriate:Donation after cardiac death versus donation after death by neurological criteria. Type of organ donation: live‐donor versus deceased donor kidney, and if appropriate: Donation after cardiac death versus donation after death by neurological criteria. Donation after cardiac death versus donation after death by neurological criteria. Participant treated: kidney donor, recipient or both participants Participant treated: kidney donor, recipient or both participants Mode of treatment delivery: non‐invasive versus invasive Mode of treatment delivery: non‐invasive versus invasive Directness of treatment: direct versus indirect Directness of treatment: direct versus indirect Timing: pre‐conditioning, per‐conditioning or post‐conditioning. Timing: pre‐conditioning, per‐conditioning or post‐conditioning. Our provisional knowledge of the evidence base indicates that many of these subgroup analyses will not be feasible because there is insufficient data to perform comparisons. Without knowing exactly what we will be able to analyse, we have elected to be broad in our candidate analyses. All of these factors are relevant and may interact with the treatment effect, and it is important to identify if certain treatments work in certain populations to inform future research and patient management. We will use the type of ischaemic conditioning performed (detailed in Types of interventions) and the type of kidney transplantation (live‐donor or deceased‐donor) as stratifying variables where appropriate. This will allow assessment of whether one modality of ischaemic conditioning is more effective or has greater potency across different populations or organ types. Subgroup analysis will be performed for critical and important outcomes, using the formal test for subgroup differences in RevMan [27]. Equity‐related assessment Many of the interventions evaluated in this review are performed around the time of organ retrieval from a deceased donor. Equity of access to an intervention for deceased donor populations is clearly an ethically complex area. Donors and their families are likely to wish for the best possible outcomes for organ recipients and, hence, would likely want access to potential treatments that could improve outcomes. As such, it is important to assess equity of access for these patients. Furthermore, access to kidney transplantation is recognised as a source of healthcare inequity [32], and included studies may apply further constraints on the included populations (either live‐donors or recipients of live‐ or deceased‐donor organs) through inclusion and exclusion criteria. Hence, we will collect, where available, data from included studies on the inclusion and exclusion criteria, age, ethnicity, spoken languages, gender/sex (as recorded), and geography of the included populations in each study. We will provide a narrative synthesis of equity of access to the included studies and how this may impact the interpretation of findings and population‐specific treatment effects, as well as summarising evidence of inequality in trial designs and, where relevant, its relevance to future research recommendations. Sensitivity analysis We will conduct sensitivity analyses for critical and important outcomes by excluding data from studies that: Are at high overall risk of bias for the outcome of interest,Have missing data for the outcome of interest. Are at high overall risk of bias for the outcome of interest, Are at high overall risk of bias for the outcome of interest, Have missing data for the outcome of interest. Have missing data for the outcome of interest. Certainty of the evidence assessment We will assess the certainty of the evidence for each outcome using the GRADE approach and GRADEpro GDT software to create summary of findings tables [31, 33]. We will present selected outcomes using summary of findings tables, anticipating the following outcomes. eGFR (late time period)Patient survival post‐transplant or death (late time period)Graft survival post‐transplant or graft loss (late time period)Transplant survival or participant death/graft loss (late time period)DGF (early time period)Serious adverse events (early time period)Participant‐reported outcome measures (intermediate time period) eGFR (late time period) eGFR (late time period) Patient survival post‐transplant or death (late time period) Patient survival post‐transplant or death (late time period) Graft survival post‐transplant or graft loss (late time period) Graft survival post‐transplant or graft loss (late time period) Transplant survival or participant death/graft loss (late time period) Transplant survival or participant death/graft loss (late time period) DGF (early time period) DGF (early time period) Serious adverse events (early time period) Serious adverse events (early time period) Participant‐reported outcome measures (intermediate time period) Participant‐reported outcome measures (intermediate time period) Two review authors (HM, MG) will independently assess the certainty of evidence, with two further review authors contributing to final decision‐making and resolving disagreements (JF, KV). The overall risk of bias judgment will inform the GRADE assessment. We will provide the rationale for downgrading certainty in the summary of findings table footnotes. Review authors who were directly involved in a trial will not perform GRADE assessments of that study. We will rate the certainty of the evidence as 'high', 'moderate', 'low', or 'very low', using the five GRADE considerations. Risk of biasIndirectness of evidenceInconsistency of resultsImprecision of effect estimatesPublication bias. Risk of bias Risk of bias Indirectness of evidence Indirectness of evidence Inconsistency of results Inconsistency of results Imprecision of effect estimates Imprecision of effect estimates Publication bias. Publication bias. Where data is insufficient to summarise findings for our identified outcomes, we will report this. Consumer involvement We will not involve consumers in this review due to limited resources, although we will use the SONG core outcome sets for the review's outcomes, which have been developed with consumer involvement [9]. Supporting Information Supplementary materials are available with the online version of this article: 10.1002/14651858.CD016342. Supplementary materials are published alongside the article and contain additional data and information that support or enhance the article. Supplementary materials may not be subject to the same editorial scrutiny as the content of the article and Cochrane has not copyedited, typeset or proofread these materials. The material in these sections has been supplied by the author(s) for publication under a Licence for Publication and the author(s) are solely responsible for the material. Cochrane accordingly gives no representations or warranties of any kind in relation to, and accepts no liability for any reliance on or use of, such material. Supplementary material 1 Search strategies